|
[Related PubMed/MEDLINE]
Total Number of Papers: 451
|
|
|
|
|
[Display Entries]
|
|
|
| |
|
[Entries Per Page]
|
|
per page
|
| |
|
Page Control
|
|
|
|
Page: of
|
|
|
|
| Abbreviation |
: CR |
| Long Form |
: controlled-release |
|
| No. |
Year |
Title |
Co-occurring Abbreviation |
| 1 |
2020 |
Amphiphilic polymer based nanoformulations of mancozeb for management of early blight in tomato. |
--- |
| 2 |
2020 |
Association Between Formulary Coverage and Use of Abuse-Deterrent Prescription Opioids, Risk for Abuse or Overdose, and Associated Healthcare Resource Utilization. |
ADF, CI, ER, HCl, OR |
| 3 |
2020 |
Beneficial Effect of Flecainide Controlled Release on the Quality of Life of Patients with Atrial Fibrillation-the REFLEC-CR Study. |
AF, CCS-SAF, PerAF, QOL |
| 4 |
2020 |
Controlled Release of Oxycodone as an Opioid Titration for Cancer Pain Relief: A Retrospective Study. |
GPM, IR, NRS |
| 5 |
2020 |
Effect of Roux-en-Y gastric bypass on the bioavailability of metoprolol from immediate and controlled release tablets: a single oral dose study before and after surgery. |
AUC, IR, RYGB |
| 6 |
2020 |
Efficacy and safety of short-term use of a pelubiprofen CR and aceclofenac in patients with symptomatic knee osteoarthritis: A double-blinded, randomized, multicenter, active drug comparative, parallel-group, phase IV, non-inferiority clinical trial. |
K-WOMAC, VAS |
| 7 |
2020 |
Oral controlled release dosage forms: dissolution versus diffusion. |
API, GI, IR, PK |
| 8 |
2020 |
Patterns of oxycodone controlled release use in older people with cancer following public subsidy of oxycodone/naloxone formulations: An Australian population-based study. |
DVA |
| 9 |
2020 |
Preparation and characterization of metformin hydrochloride controlled-release tablet using fatty acid coated granules. |
ALS, MFM, MFM-CRT, micro-CT, PEO |
| 10 |
2020 |
Risk factors of infective endocarditis in persons who inject drugs. |
IE, PWID |
| 11 |
2020 |
Segmental-Dependent Solubility and Permeability as Key Factors Guiding Controlled Release Drug Product Development. |
BCS, GIT, IR, PAMPA |
| 12 |
2020 |
Tapentadol vs oxycodone for postoperative pain treatment the first 7 days after total knee arthroplasty: a randomized clinical trial. |
ER, IQR |
| 13 |
2019 |
A gastrointestinal simulation system for dissolution of oral solid dosage forms before and after Roux-en-Y gastric bypass. |
GISS, IR, RYGB |
| 14 |
2019 |
Bayesian knowledge integration for an in vitro-in vivo correlation model. |
IR, IVIVC, ODEs, PK, TD |
| 15 |
2019 |
Development and evaluation of dexibuprofen formulation with fast onset and prolonged effect. |
HPMC, SLS |
| 16 |
2019 |
Increases in controlled-release oxycodone utilisation following the subsidy of oxycodone with naloxone formulations: An Australian population-based study. |
RD |
| 17 |
2019 |
Outcomes Associated with Treatment of Chronic Pain with Tapentadol Compared with Morphine and Oxycodone: A UK Primary Care Observational Study. |
CPRD, HES, IRRs, PR |
| 18 |
2019 |
Physiologically based absorption modeling to predict bioequivalence of controlled release and immediate release oral products. |
BE, GI, IR |
| 19 |
2019 |
Randomized, crossover questionnaire survey of acceptabilities of controlled-release mesalazine tablets and granules in ulcerative colitis patients. |
UC |
| 20 |
2019 |
Will controlled release mebeverine be able to surpass placebo in treatment of diarrhoea predominant irritable bowel syndrome? |
IBS, IBS-D, IBS-QOL, NoBM7d, OPD |
| 21 |
2018 |
A Double-Blind, Placebo-Controlled, Phase II Study to Determine the Efficacy, Safety, Tolerability and Pharmacokinetics of a Controlled Release (CR) Formulation of Mazindol in Adults with DSM-5 Attention-Deficit/Hyperactivity Disorder (ADHD). |
ADHD, CGI-I, HR, MINI |
| 22 |
2018 |
Cebranopadol: A Novel, First-in-Class, Strong Analgesic: Results from a Randomized Phase IIa Clinical Trial in Postoperative Acute Pain. |
IMP, NOP, SPI, TEAE |
| 23 |
2018 |
Comparative effectiveness of switching paroxetine formulation for treatment of major depressive disorder: an open-label multicenter study. |
ADRs, CGI-S, IR, MDD |
| 24 |
2018 |
Efficacy and safety of tapentadol prolonged release formulation in the treatment of elderly patients with moderate-to-severe chronic osteoarthritis knee pain: a pooled analysis of two double-blind, randomized, placebo-, and active-controlled trials. |
OA, PR |
| 25 |
2018 |
Efficacy, tolerability and acceptability of oxycodone for cancer-related pain in adults: an updated Cochrane systematic review. |
--- |
| 26 |
2018 |
Evaluation of the effects of food on levodropropizine controlled-release tablet and its pharmacokinetic profile in comparison to that of immediate-release tablet. |
AEs, CIs, GMRs, IR, PK |
| 27 |
2018 |
Person-level changes in oxycodone use after the introduction of a tamper-resistant formulation in Australia. |
CI, HR, IRR, OR |
| 28 |
2018 |
PLGA nanoparticles are effective to control the colonic release and absorption on ibuprofen. |
NPs, PLGA |
| 29 |
2018 |
Preclinical models for colonic absorption, application to controlled release formulation development. |
--- |
| 30 |
2017 |
An innovative method for the preparation of high API-loaded hollow spherical granules for use in controlled-release formulation. |
API, PSD |
| 31 |
2017 |
Assessing the impact of prescribing directives on opioid prescribing practices among Veterans Health Administration providers. |
FDA, VHA |
| 32 |
2017 |
Blend Hydrogel Microspheres of Carboxymethyl Chitosan and Gelatin for the Controlled Release of 5-Fluorouracil. |
5-FU, CMCS, DSC, FTIR, GA, GE, SEM, XRD |
| 33 |
2017 |
Clinical evaluation of ropinirole controlled-release formulation at 18-24mg/day in Japanese patients with Parkinson's disease. |
--- |
| 34 |
2017 |
Comparison of ambulatory blood pressure-lowering effects of higher doses of different calcium antagonists in uncontrolled hypertension: the Calcium Antagonist Controlled-Release High-Dose Therapy in Uncontrolled Refractory Hypertensive Patients (CARILLON) Study. |
BP, CARILLON |
| 35 |
2017 |
Conversion to carbidopa and levodopa extended-release (IPX066) followed by its extended use in patients previously taking controlled-release carbidopa-levodopa for advanced Parkinson's disease. |
CD-LD, IR, PD |
| 36 |
2017 |
Dialyzability of Oxycodone and Its Metabolites in Chronic Noncancer Pain Patients with End-Stage Renal Disease. |
HD, HDF |
| 37 |
2017 |
Efficacy and Safety of Different Aceclofenac Treatments for Chronic Lower Back Pain: Prospective, Randomized, Single Center, Open-Label Clinical Trials. |
CLBP, EQ-5D, ODI, VAS |
| 38 |
2017 |
Efficacy and Safety of Once-Daily Controlled-Release Pregabalin for the Treatment of Patients With Postherpetic Neuralgia: A Double-Blind, Enriched Enrollment Randomized Withdrawal, Placebo-Controlled Trial. |
LTR |
| 39 |
2017 |
Interleukin-6 increases the expression of key proteins associated with steroidogenesis in human NCI-H295R adrenocortical cells. |
AP-1, IL-6, JAK, SE, SF-1, StAR, STAT |
| 40 |
2017 |
Mechanistic Approach to Understanding the Influence of USP Apparatus I and II on Dissolution Kinetics of Tablets with Different Operating Release Mechanisms. |
IR |
| 41 |
2017 |
Nanomedicine for prostate cancer using nanoemulsion: A review. |
NE, PCa |
| 42 |
2017 |
Oxycodone for cancer-related pain. |
CENTRAL, CI, IR, RR, SMD |
| 43 |
2017 |
Single- and multiple-dose pharmacokinetics and tolerability of a paroxetine controlled-release tablet in healthy Chinese subjects
. |
--- |
| 44 |
2017 |
Tapentadol prolonged-release for moderate-to-severe chronic osteoarthritis knee pain: a double-blind, randomized, placebo- and oxycodone controlled release-controlled study. |
LS, PR |
| 45 |
2016 |
Alternative methods for CYP2D6 phenotyping: comparison of dextromethorphan metabolic ratios from AUC, single point plasma, and urine. |
DM, MRDM/DX, MRs |
| 46 |
2016 |
Controlled release drug delivery systems to improve post-operative pharmacotherapy. |
LAs, NSAIDs |
| 47 |
2016 |
Cost-effectiveness analysis of oxycodone with naloxone versus oxycodone alone for the management of moderate-to-severe pain in patients with opioid-induced constipation in Canada. |
OIC, QALYs |
| 48 |
2016 |
Eco-friendly PEG-based controlled release nano-formulations of Mancozeb: Synthesis and bioefficacy evaluation against phytopathogenic fungi Alternaria solani and Sclerotium rolfsii. |
ED50, PEGs |
| 49 |
2016 |
Effects of Zolpidem CR on Sleep and Nocturnal Ventilation in Patients with Heart Failure. |
AHI |
| 50 |
2016 |
Efficacy and safety of fulranumab as monotherapy in patients with moderate to severe, chronic knee pain of primary osteoarthritis: a randomised, placebo- and active-controlled trial. |
DB, FDA, NGF, OA, OAPI |
| 51 |
2016 |
Patient-relevant outcomes and health-related quality of life in patients with chronic, severe, noncancer pain treated with tapentadol prolonged release-Using criteria of health technology assessment. |
HRQoL, MID, PR, RR |
| 52 |
2016 |
The Adverse Events of Oxycodone in Cancer-Related Pain: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. |
AEs, CIs, Mc, RR |
| 53 |
2016 |
The Controlled Release of Drugs and Bioactive Compounds from Mesoporous Silica Nanoparticles. |
MSNs |
| 54 |
2016 |
Utility of PBPK Absorption Modeling to Guide Modified Release Formulation Development of Gaboxadol, a Highly Soluble Compound With Region-Dependent Absorption. |
IR, PBPK |
| 55 |
2015 |
"Rolling" phenomenon in twin screw granulation with controlled-release excipients. |
--- |
| 56 |
2015 |
A Retrospective, Pooled Suicidality Evaluation of Ropinirole Immediate Release and Controlled Release for the Treatment of Restless Legs Syndrome. |
IR, RLS |
| 57 |
2015 |
Analysis of the impact of controlled release formulations on oral drug absorption, gut wall metabolism and relative bioavailability of CYP3A substrates using a physiologically-based pharmacokinetic model. |
AUC, IR, PBPK |
| 58 |
2015 |
Application of physiologically based pharmacokinetic modeling in the prediction of pharmacokinetics of bicyclol controlled-release formulation in human. |
IR, PBPK, PK |
| 59 |
2015 |
Controlled release of therapeutics using interpenetrating polymeric networks. |
IPN |
| 60 |
2015 |
Design and in vivo evaluation of oxycodone once-a-day controlled-release tablets. |
HPMC |
| 61 |
2015 |
Development and preliminary validation of an integrated efficacy-tolerability composite measure for the evaluation of analgesics. |
AEs, ER, ETC |
| 62 |
2015 |
Development of controlled release nanoformulations of carbendazim employing amphiphilic polymers and their bioefficacy evaluation against Rhizoctonia solani. |
PEGs, POA, WP |
| 63 |
2015 |
Effect of the gastrointestinal prokinetic agent erythromycin on the pharmacokinetics of pregabalin controlled-release in healthy individuals: a phase I, randomized crossover trial. |
--- |
| 64 |
2015 |
Electrospun nanofibers as a potential controlled-release solid dispersion system for poorly water-soluble drugs. |
DSC, HPMC, PRX, SD, SEM, XPRD |
| 65 |
2015 |
In Situ Perfusion Model in Rat Colon for Drug Absorption Studies: Comparison with Small Intestine and Caco-2 Cell Model. |
Fa |
| 66 |
2015 |
Long-term safety and efficacy of high-dose controlled-release nifedipine (80 mg per day) in Japanese patients with essential hypertension. |
BID, BP, CCB |
| 67 |
2015 |
Long-term Safety and Efficacy of Tapentadol Extended Release Following up to 2 Years of Treatment in Patients With Moderate to Severe, Chronic Pain: Results of an Open-label Extension Trial. |
ER |
| 68 |
2015 |
Multiple-Dose Study to Evaluate Pharmacokinetics, Pharmacodynamics, and Safety in Healthy Subjects: A Comparison of Controlled-Release Sarpogrelate and Immediate-Release Sarpogrelate. |
IR |
| 69 |
2015 |
Opioid Concentrations in Oral Fluid and Plasma in Cancer Patients With Pain. |
OFL, TD |
| 70 |
2015 |
Oxycodone for cancer-related pain. |
CENTRAL, CI, ICTRP, IR, mRCT, SMD |
| 71 |
2015 |
Pharmacoscintigraphy studies to assess the feasibility of a controlled release formulation of ziprasidone. |
CCSD |
| 72 |
2015 |
Safety and effectiveness of controlled-release paroxetine in routine clinical practice: results of a postmarketing surveillance study of patients with depression. |
CGI-GI, CGI-SI, CI |
| 73 |
2015 |
Successful interventions in decreasing oxycodone CR prescriptions within an underserved population. |
--- |
| 74 |
2015 |
Tolerability and efficacy of tapentadol extended release in elderly patients ≥ 75 years of age with chronic osteoarthritis knee or low back pain. |
ER, TEAEs |
| 75 |
2014 |
Applications of linking PBPK and PD models to predict the impact of genotypic variability, formulation differences, differences in target binding capacity and target site drug concentrations on drug responses and variability. |
PBPK, PDs, PKs |
| 76 |
2014 |
Changes in prevalence of prescription opioid abuse after introduction of an abuse-deterrent opioid formulation. |
ADF, CI, ER, RR |
| 77 |
2014 |
Clinical and economic evaluation of tapentadol extended release and oxycodone/naloxone extended release in comparison with controlled release oxycodone in musculoskeletal pain. |
CNS, ER, GE, QALY, RCTs |
| 78 |
2014 |
Comparison of the efficacy and safety profile of morning administration of controlled-release simvastatin versus evening administration of immediate-release simvastatin in chronic kidney disease patients with dyslipidemia. |
CKD, IR |
| 79 |
2014 |
Controlled release of therapeutic antibody formats. |
CNS |
| 80 |
2014 |
Controlled-release oxycodone versus naproxen at home after ambulatory surgery: a randomized controlled trial. |
--- |
| 81 |
2014 |
Design, in vitro release characterization and pharmacokinetics of novel controlled release pellets containing levodropropizine. |
IR, LDP, SR |
| 82 |
2014 |
Development of Process Analytical Technology (PAT) methods for controlled release pellet coating. |
API, CQAs, NIR, PAT, QbD |
| 83 |
2014 |
Effects of aprepitant on the pharmacokinetics of controlled-release oral oxycodone in cancer patients. |
--- |
| 84 |
2014 |
Efficacy and Safety of Aceclofenac Controlled Release in Patients with Knee Osteoarthritis: A 4-week, Multicenter, Randomized, Comparative Clinical Study. |
IR, KOOS, OA, ROM, VAS |
| 85 |
2014 |
Efficacy and tolerability of controlled-release oxycodone for oxaliplatin-induced peripheral neuropathy and the extension of FOLFOX therapy in advanced colorectal cancer patients. |
CRC, OIPN |
| 86 |
2014 |
Evaluation of blood pressure and heart rate in patients with hypertension who received tapentadol extended release for chronic pain: a post hoc, pooled data analysis. |
bpm, DBP, ER, SBP, SE |
| 87 |
2014 |
Guar gum as platform for the oral controlled release of therapeutics. |
GG |
| 88 |
2014 |
Influence of formulation on mobility of metazachlor in soil. |
SC |
| 89 |
2014 |
Nifedipine controlled-release 40 mg b.i.d. in Japanese patients with essential hypertension who responded insufficiently to nifedipine controlled-release 40 mg q.d.: a phase III, randomized, double-blind and parallel-group study. |
BP, DBP |
| 90 |
2014 |
Once daily controlled-release pregabalin in the treatment of patients with fibromyalgia: a phase III, double-blind, randomized withdrawal, placebo-controlled study. |
AE, LTR |
| 91 |
2014 |
Pharmacokinetics of pregabalin controlled-release in healthy volunteers: effect of food in five single-dose, randomized, clinical pharmacology studies. |
IR |
| 92 |
2014 |
Pregabalin controlled-release pharmacokinetics in healthy volunteers: analysis of four multiple-dose randomized clinical pharmacology studies. |
AUC24, IR |
| 93 |
2014 |
Safety and tolerability of tapentadol extended release in moderate to severe chronic osteoarthritis or low back pain management: pooled analysis of randomized controlled trials. |
AEs, ER, HCl, TEAE |
| 94 |
2014 |
Study the effect of formulation variables on drug release from hydrophilic matrix tablets of milnacipran and prediction of in-vivo plasma profile. |
DE, HPMC, MDT, MRT |
| 95 |
2014 |
Tapentadol prolonged release for managing moderate to severe, chronic malignant tumor-related pain. |
CI, OR, PR, TEAEs |
| 96 |
2014 |
The controlled release of bioactive compounds from lignin and lignin-based biopolymer matrices. |
--- |
| 97 |
2013 |
A pooled analysis of patient-specific factors and efficacy and tolerability of tapentadol extended release treatment for moderate to severe chronic pain. |
BMI, ER |
| 98 |
2013 |
A Randomized Phase I Evaluation of CTP-499, a Novel Deuterium-Containing Drug Candidate for Diabetic Nephropathy. |
DN |
| 99 |
2013 |
Assessment of pharmacodynamic effects following oral administration of crushed morphine sulfate and naltrexone hydrochloride extended-release capsules compared with crushed morphine sulfate controlled-release tablets and placebo in nondependent recreational opioid users. |
MSN, PK |
| 100 |
2013 |
Budget impact analysis of tapentadol extended release for the treatment of moderate to severe chronic noncancer pain. |
ER, OISEs, PMPM |
|
A Search Service for Abbreviation / Long Form
